Palvella Therapeutics Inc
Research Palvella Therapeutics Inc (PVLA) on Bullrun: market cap USD 2.13B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPVLA
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 2.13B
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 21.87M
- Free cash flow-USD 12.85M
Valuation Snapshot
latest market cap is USD 2.13B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 41.72M | -USD 25.01M | n/a | -3.71 | USD 57.98M | USD 633.00K | USD 27.98M |
| FY2024 | USD 0 | -USD 17.43M | -USD 10.84M | n/a | -7.83 | USD 83.60M | USD 0 | USD 62.61M |
| FY2023 | USD 42.81M | USD 18.69M | -USD 13.87M | n/a | 2.17 | USD 7.35M | n/a | -USD 74.48M |
| FY2022 | USD 25.90M | -USD 33.28M | -USD 60.97M | n/a | n/a | USD 38.64M | n/a | -USD 93.78M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 2.13B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.30B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 132.15M | n/a | n/a | n/a |
About Palvella Therapeutics Inc
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Palvella Therapeutics Inc's market cap?
Palvella Therapeutics Inc's market capitalization is USD 2.13B.
What does Palvella Therapeutics Inc do?
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations.